Antibody-drug Conjugates (ADC)

Fmoc-NH-ethyl-SS-propionic NHS ester is a cleavable linker designed for use in antibody-drug conjugate (ADC) synthesis. This reagent facilitates the conjugation of therapeutics to antibodies while enabling targeted delivery and controlled release of the drug within the cellular environment. Its unique structure allows for effective cleavage, making it ideal for applications in cancer research and therapeutic development involving ADCs.

N-trifluoroacetyl-β-alanyl chloride is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, enhancing the therapeutic efficacy of ADCs. Its application in drug development research aids in the creation of targeted therapies for cancer treatment and other diseases.

Propargyl-C8-amido-PEG2-NHS ester is a non-cleavable linker designed for use in antibody-drug conjugates (ADCs) with a primary mechanism of enabling stable conjugation through click chemistry. This reagent contains an alkyne functional group, allowing for efficient copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules. Its application spans the development of targeted therapies by facilitating the precise attachment of cytotoxic drugs to antibodies, enhancing therapeutic efficacy while minimizing off-target effects.

2-Hydroxyethyl disulfide mono-tosylate is a cleavable linker designed for antibody-drug conjugate (ADC) synthesis. It facilitates the selective conjugation of cytotoxic agents to antibodies, enabling targeted delivery to cancer cells. This compound is instrumental in advancing research on ADC formulations and therapeutic strategies in oncology.

DMAC-PDB is a cleavable ADC linker that facilitates the construction of antibody-drug conjugates (ADCs). This reagent is designed to promote targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. It serves as a valuable tool in the development of ADCs for cancer research, enabling the precise linking of antibodies to payloads for improved specificity in therapeutic applications.

Me-Tetrazine-Me-Ph-amide-Lys(Boc)-Lys-N3 is an innovative ADC linker that facilitates the construction of antibody-drug conjugates (ADCs). This reagent provides a robust mechanism for site-specific conjugation, enhancing the therapeutic efficacy of ADCs. It is particularly useful in research applications focused on targeted cancer therapies and precision medicine.

Boc-aminooxy-amide-PEG4-propargyl is a non-cleavable linker designed for antibody-drug conjugate (ADC) synthesis, featuring a 4-unit polyethylene glycol (PEG) backbone. This compound includes an alkyne functional group, facilitating its use in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its robust chemical properties make it suitable for the development of targeted therapies in oncology research and bioconjugation applications.

Bis-SS-C3-sulfo-NHS ester is a cleavable linker designed for the development of antibody-drug conjugates (ADCs). This compound is pivotal in facilitating selective drug delivery by connecting cytotoxic agents to antibodies via a disulfide bond, ensuring targeted release within the tumor microenvironment. It is widely applied in research focused on ADC formulation and optimization strategies in cancer therapeutics.

Mal-amido-PEG9-Val-Ala-PAB-SG3200 is a cleavable linker designed for use in antibody-drug conjugates (ADCs). Its structural features enable selective release of therapeutic agents upon cleavage, enhancing targeted drug delivery. This linker is crucial for research applications focusing on the development and optimization of ADC formulations.

MC-Gly-Gly-Phe-OSu is an ADC linker that facilitates the conjugation of antibody-drug complexes. It demonstrates key biological activity by enhancing the targeting of cytotoxic agents to cancer cells, thereby improving therapeutic efficacy. This compound is primarily utilized in research applications focused on antibody-drug conjugate development for cancer treatment.

AcLys-PABC-VC-Aur0101 intermediate-1 is a cathepsin-cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates targeted drug delivery by ensuring the release of the cytotoxic drug within the tumor microenvironment upon cathepsin-mediated cleavage. It is essential for enhancing the efficacy and specificity of ADCs in cancer therapeutics, providing researchers with a valuable tool for developing novel therapies.

4-Succinimidyl-oxycarbonyl-α-(2-pyridyldithio)toluene functions as a non-cleavable linker in the fabrication of antibody-drug conjugates (ADCs). This compound enables the stable attachment of cytotoxic payloads to monoclonal antibodies, thereby enhancing the therapeutic efficacy of the resulting ADCs. It is particularly useful in developing targeted cancer therapies where the controlled delivery of drugs is paramount for minimizing off-target effects.

Mal-L-Dap(Boc)-OSu is an ADC linker that facilitates the conjugation of antibodies to cytotoxic agents. Its primary mechanism involves forming stable bonds that enhance the efficacy and selectivity of antibody-drug conjugates (ADCs). This reagent is essential for researchers developing targeted therapies in oncology and other applications where precision delivery of therapeutics is critical.

Glucocorticoid receptor agonist-1 phosphate Gly-Glu TFA is a cleavable linker designed for the synthesis of Antibody-Drug Conjugates (ADCs). This compound facilitates targeted drug delivery by linking cytotoxic agents to antibodies, enhancing therapeutic efficacy while minimizing off-target effects. Its ability to be cleaved under specific physiological conditions makes it a valuable tool in the development of precision medicine strategies.

MP-PEG4-VK(Boc)G-OSu is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It provides site-specific attachment of drug molecules to antibodies, allowing for targeted delivery of therapeutics to cancer cells. This linker is particularly valuable in the development of ADCs aimed at enhancing the efficacy and reducing the off-target effects of cancer treatment.

DL002 is an antibody-drug conjugate (ADC) linker designed for the synthesis of conjugates featuring BCL-2 family protein degraders. It plays a critical role in tumor research by facilitating targeted delivery of cytotoxic agents, thereby enhancing therapeutic efficacy. This reagent is essential for studies aiming to investigate the modulation of BCL-2 proteins in cancer treatment strategies.

m-PEG2-Tos is an uncleavable linker targeting antibody-drug conjugates (ADCs). This PEG-based compound facilitates the conjugation of therapeutic agents to antibodies, enhancing delivery and efficacy in targeted therapy. Additionally, m-PEG2-Tos can be utilized as a linker in the synthesis of PROTACs, contributing to the development of tailored degradation strategies in cellular studies.

Propargyl-PEG1-SS-PEG1-PFP ester is a cleavable linker designed for use in antibody-drug conjugates (ADCs), facilitating the targeted delivery of therapeutic agents. Featuring a propargyl group, this reagent allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, making it particularly useful for bioconjugation applications. Its versatile structure enables enhanced stability and controlled release in therapeutic settings.

Fmoc-Asn-Pro-Val-PABC-PNP is an ADC linker designed for antibody-drug conjugate (ADC) applications. This reagent facilitates the efficient conjugation of cytotoxic agents to antibodies, enhancing targeted delivery to cancer cells. Its structure and properties make it suitable for research in drug development and therapeutic efficacy studies.

Cyclooctyne-O-amido-PEG2-PFP ester is a non-cleavable linker designed for antibody-drug conjugates (ADCs), utilizing a 2-unit polyethylene glycol (PEG) structure. This compound serves as a versatile click chemistry reagent, possessing an alkyne group that enables efficient copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing biomolecules. Its application is critical for the development of targeted therapies, enhancing the delivery and efficacy of cytotoxic agents in ADC formulations.

LC-PEG8-SPDP is a cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates the attachment of therapeutic agents to antibodies, promoting targeted delivery and enhancing the efficacy of treatments. Its biocompatibility and water solubility make it suitable for research applications focused on ADC development and optimization in cancer therapeutics.

Mal-PEG3-VCP-NB is a degradable antibody-drug conjugate (ADC) linker characterized by its maleimide functional group, a three-unit polyethylene glycol (PEG) spacer, and a valine-citrulline (VCP) cleavage site. This compound facilitates site-specific conjugation to antibodies, enhancing the therapeutic efficacy of ADCs while allowing for controlled release of cytotoxic agents. It is primarily utilized in the development of ADCs for targeted cancer therapies.

BCN-exo-PEG2-maleimide is an ADC linker characterized by the presence of two PEG units and a bidentate macrocyclic ligand, BCN. This compound facilitates the formation of stable triazole linkages through click chemistry by reacting with azide-containing molecules, and operates without the need for catalysts. Its maleimide group is hydrolytically labile in aqueous environments, making it suitable for applications in drug delivery and bioconjugation studies.

Propargyl-O-C1-amido-PEG4-C2-NHS ester is a non-cleavable 4-unit PEG linker designed for antibody-drug conjugation (ADC) applications. This compound features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with azide-containing molecules. Its properties make it suitable for the development of stable and effective ADCs in therapeutic research.

Propargyl-O-C1-amido-PEG3-C2-NHS ester is a non-cleavable PEG-based linker that targets the synthesis of antibody-drug conjugates (ADCs). Featuring an alkyne group, it serves as a click chemistry reagent and is capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. This compound is essential for creating stable ADC structures, enhancing drug delivery and efficacy in therapeutic applications.

DMAC-SPDB-sulfo is a cleavable linker specifically designed for use in the synthesis of antibody-drug conjugates (ADCs). This sulfo-based compound facilitates the controlled release of therapeutic agents upon cellular internalization, allowing for targeted delivery and enhanced efficacy. Researchers can utilize DMAC-SPDB-sulfo in the development of ADCs to improve treatment precision in various cancer therapies, aiding in the advancement of targeted drug delivery systems.

cBu-Cit-OH is a cyclic alkene-based linker designed for antibody-drug conjugate (ADC) applications. This reagent facilitates the stable attachment of cytotoxic agents to antibodies, enhancing targeted delivery and efficacy in cancer therapeutics. Its unique structural properties enable effective conjugation, making it suitable for the synthesis and development of innovative ADCs in research settings.

Ald-Ph-amido-C2-nitrate is a non-cleavable ADC linker designed for antibody-drug conjugates (ADCs). This compound facilitates stable attachment between antibodies and cytotoxic agents, enhancing the efficacy of targeted cancer therapies. Its unique thiazolidine structure provides robust performance in the development of innovative therapeutic strategies.

Bis-PEG2-PFP ester is a non-cleavable linker that comprises two units of polyethylene glycol (PEG) and is essential for the synthesis of antibody-drug conjugates (ADCs). Its unique structure makes it suitable for use in peptide-based PROTACs (Proteolysis Targeting Chimeras), facilitating targeted degradation of specific proteins. This reagent supports advanced research in the fields of targeted therapy and protein regulation.

Mal-amido-PEG3-C1-NHS ester is a non-cleavable 3-unit polyethylene glycol (PEG) linker designed for antibody-drug conjugate (ADC) synthesis. This reactive NHS ester facilitates the conjugation of cytotoxic agents to antibodies, enabling targeted delivery for enhanced therapeutic efficacy. Its application is crucial in the development of ADCs aimed at improving treatment outcomes in various cancers.

Fmoc-Ala-Ala-Ala-amide-C-O-C-COOH functions as a cleavable linker for antibody-drug conjugates (ADCs). This compound enables the selective release of cytotoxic drugs upon internalization by target cells, enhancing the efficacy and specificity of cancer therapies. It is widely used in the development of ADCs for various research applications, including targeted delivery and controlled drug release studies.

MC-Val-Cit-PAB-NH-C2-NH-Boc is a cathepsin-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates targeted delivery of cytotoxic agents by enabling selective release upon cleavage in the tumor microenvironment. Its application in ADC development supports research in cancer therapeutics and targeted drug delivery mechanisms.

Ald-Ph-amido-PEG3-NHS ester is a non-cleavable three-unit polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the stable attachment of cytotoxic agents to antibodies, thereby enhancing targeted delivery and minimizing systemic toxicity. It is essential for researchers developing ADCs aimed at improving therapeutic efficacy in cancer treatment and other diseases.

Sulfo-SIAB sodium is a non-cleavable monovalent bilinker designed for antibody-drug conjugate (ADC) applications. This linker facilitates the stable attachment of drugs to antibodies, ensuring enhanced therapeutic efficacy and reduced off-target effects. It is particularly useful in the development of ADCs for targeted cancer therapies and other biopharmaceuticals that require precise delivery of active compounds.

Fmoc-Phe-Lys(Trt)-PAB is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the selective delivery of therapeutic agents to targeted cells, enhancing the efficacy and minimizing off-target effects of the treatment. Its unique structure allows for the release of the drug upon cleavage, making it an essential component in the development of ADCs for cancer therapy and other applications in targeted treatment strategies.

m-PEG9-Amine is a polyethylene glycol (PEG)-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker facilitates the attachment of biomolecules, enabling targeted protein degradation and precise delivery of therapeutic agents. m-PEG9-Amine is essential for advancing research in targeted therapy and bioconjugation applications.

Mal-PEG4-VA is a cleavable ADC linker featuring a Maleimide moiety, which enables the selective conjugation of drugs to antibodies. This compound is primarily utilized in the synthesis of antibody-drug conjugates (ADCs), facilitating targeted therapeutic strategies in cancer treatment. Its ability to release the drug in response to specific stimuli enhances the therapeutic efficacy of ADCs while minimizing off-target effects.

Fmoc-Ala-Ala-Asn(Trt)-OH is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the selective attachment of cytotoxic agents to antibodies, enabling targeted delivery and enhanced therapeutic efficacy. Its application in ADC development supports research in cancer therapeutics and personalized medicine.

Bis-PEG17-NHS ester is a PEG-based linker designed for efficient conjugation in both PROTAC and antibody-drug conjugate (ADC) synthesis. Its NHS ester functionality allows for selective coupling to amine-containing molecules, facilitating the development of targeted therapies. This reagent is particularly useful in the development of PROTACs for targeted protein degradation and in the construction of ADCs that deliver cytotoxic agents to specific cancer cells.

Phe-Lys(Trt)-PAB is a peptide-based linker designed for use in antibody-drug conjugates (ADCs), featuring a cleavable bond for targeted drug release. This cathepsin-sensitive linker enhances the stability and efficacy of ADCs by facilitating payload release in the tumor microenvironment. It is suitable for research applications involving ADC development and optimization.

PAB-Ala-Val-CO-C2-mal is a cleavable antibody-drug conjugate (ADC) linker designed for the synthesis of targeted therapeutics. By facilitating the selective release of cytotoxic agents upon internalization, this linker enhances the efficacy of ADCs while minimizing off-target effects. Its application is pivotal in developing innovative cancer treatments through precise delivery mechanisms.

NMS-P945 is a reactive linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the conjugation to monoclonal antibodies (mAbs) with a reproducible Drug Antibody Ratio (DAR) exceeding 3.5. This compound enhances the efficacy and stability of ADCs, making it a valuable tool in targeted cancer therapy research applications.

NHPI-PEG3-C2-Pfp ester is a non-cleavable linker composed of a three-unit polyethylene glycol (PEG) chain designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the stable attachment of drug molecules to antibodies, enhancing therapeutic efficacy while minimizing off-target effects. Its unique structure allows for improved solubility and biocompatibility, making it suitable for various applications in drug development and cancer therapeutics.

Propargyl-PEG4-CH2CH2-Boc is a non-cleavable ADC linker designed for the synthesis of antibody-drug conjugates (ADCs) targeting Galectin-3. This versatile linker incorporates PEG and an alkyl/ether moiety, making it suitable for the development of PROTACs (PROteolysis TArgeting Chimeras). As a click chemistry reagent, it features an alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing compounds, enhancing the efficacy of bioconjugation processes in chemical biology research.

SPDP-sulfo is a cleavable ADC linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates targeted drug delivery by linking cytotoxic agents to antibodies, ensuring selective action against specific tumor cells. Its ability to undergo cleavage in the reducing environment of the target cells makes it suitable for applications in cancer research and therapeutic development.

EGGGG-PEG8-amide-bis(deoxyglucitol) is a cleavable linker designed for antibody-drug conjugates (ADCs). This reagent facilitates targeted delivery of cytotoxic agents to specific cells, enhancing therapeutic efficacy while minimizing off-target effects. It is suitable for research involving ADC development and optimization in cancer therapy.

N-Boc-PEG9-alcohol is a polyethylene glycol (PEG)-based linker utilized in the synthesis of antibody-drug conjugates (ADCs) and PROTACs. This cleavable linker facilitates the conjugation of bioactive molecules, enhancing the pharmacokinetic properties of ADCs. Its application extends to the development of targeted degraders, making it a valuable tool in chemical biology and drug discovery research.

Ald-CH2-PEG5-azide is a non-cleavable linker consisting of a five-unit polyethylene glycol (PEG) chain, specifically designed for use in antibody-drug conjugates (ADCs). This compound incorporates an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules and those containing DBCO or BCN groups. Its versatile reactivity makes it a valuable tool for the efficient synthesis of ADCs, facilitating targeted drug delivery in research applications.

Azide-C2-Azide is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). Functioning through click chemistry, it features an azide group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with compounds possessing alkyne functionalities. Additionally, Azide-C2-Azide is capable of undergoing strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN-containing molecules, making it a versatile tool in chemical biology and drug development applications.

SC-Val-Cit-PAB is a cleavable linker designed for antibody-drug conjugates (ADCs), facilitating targeted delivery of cytotoxic agents to cancer cells. It undergoes enzymatic cleavage, releasing the drug within the tumor microenvironment, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. This reagent is essential for research in developing innovative ADC formulations for cancer treatment.